Gerrit Klaerner, Tricida CEO (Nasdaq)
November 16, 2022 07:09 AM EST
People
R&D

First came the news of strate­gic re­view. Now Tri­ci­da is let­ting more than half of its staff go in wake of PhI­II flop

Amber Tong

As the de­ci­sive de­feat of its lead and sole drug con­tin­ues to re­ver­ber­ate, Tri­ci­da is lay­ing off 57% of its work­force while it search­es for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

A service from the Financial Times